Are long-acting intramuscular testosterone injections safe?

Testosterone substitution in male hypogonadism is a recognized tool to treat symptomatic patients. Various forms of this treatment exist including a long-acting intramuscular form using testosterone undecanoate given at approximately 3-monthly intervals. Safety aspects inherent to the intramuscular injection of a medication in an oily vehicle have to be recognized.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

206,07 € per year

only 17,17 € per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Middleton, T. et al. Complications of injectable testosterone undecanoate in routine clinical practice. Eur. J. Endocrinol.172, 511–517 (2015). ArticleCASGoogle Scholar
  2. Svendsen, O. & Aaes-Jørgensen, T. Studies on the fate of vegetable oil after intramuscular injection into experimental animals. Acta Pharmacol. Toxicol. (Copenh.)45, 352–378 (1979). ArticleCASGoogle Scholar
  3. Svendsen, O., Dencker, S. J., Fog, R., Gravem, A. O. & Kristjansen, P. Microscopic evidence of lymphogenic absorption of oil in humans receiving neuroleptic oily depot preparations intramuscularly. Acta Pharmacol. Toxicol. (Copenh.)47, 157–158 (1980). ArticleCASGoogle Scholar
  4. Bron, K. M., Baum, S. & Abrams, H. L. Oil embolism in lymphangiography. Incidence, manifestations, and mechanisms. Radiology80, 194–202 (1963). ArticleCASGoogle Scholar
  5. Mackey, M. A., Conway, A. J. & Handelsman, D. J. Tolerability of intramuscular injections of testosterone ester in an oil vehicle. Hum. Reprod.10, 862–865 (1995). ArticleCASGoogle Scholar
  6. Zitzmann, M. et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J. Sex. Med.10, 579–588 (2013). ArticleCASGoogle Scholar
  7. Bachman, E. et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J. Gerontol. A Biol. Sci. Med. Sci.69, 725–735 (2014). ArticleCASGoogle Scholar
  8. Coviello, A. D. et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J. Clin. Endocrinol. Metab.93, 914–919 (2008). ArticleCASGoogle Scholar
  9. Jockenhövel, F., Vogel, E., Reinhardt, W. & Reinwein, D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur. J. Med. Res.2, 293–298 (1997). PubMedGoogle Scholar
  10. Dobs, A. S. et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab.84, 3469–3478 (1999). CASPubMedGoogle Scholar

Author information

Authors and Affiliations

  1. Centre for Reproductive Medicine and Andrology/Clinical Andrology, University Clinics Münster, Domagkstraße 11, 48149, Münster, Germany Michael Zitzmann
  1. Michael Zitzmann